Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

China’s New Stem Cell Guidelines To Shake Up Industry?

This article was originally published in PharmAsia News

Executive Summary

China is releasing additional regulations governing clinical trials with stem cell therapies following its first new administrative measures this year, in order to better regulate the market. The changes are expected to result in a reshuffle of the industry and the flushing out of up to 80% of companies currently involved in the field, with the focus of the supply chain set to shift to the middle ground.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel